CDMOs in Italy: 31 compared (2026)
31 of the 255 contract development and manufacturing organisations in A4BEE’s European census are headquartered in Italy. The largest, with revenue over €1bn, are ACS Dobfar, Biofarma Group, BSP Pharmaceuticals, F.I.S. Fabbrica Italiana Sintetici, Olon and Patheon Italia. 16 sit between €250m and €1bn and 9 are smaller or niche.
By ownership: 12 family-owned, 7 private equity, 2 listed and 10 part of a pharma or industrial group. The most common capabilities are small-molecule API (18), oral solid dose (16), sterile fill-finish (12), biologics and biosimilars (7) and peptide (5). 21 of the 31 rows rest on audited reports or official company disclosures; the rest come from secondary sources or estimates.
31 companies
CDMOs in Italy
| Company | HQ | Ownership | Size | Revenue (as reported) | Modalities | Data |
|---|---|---|---|---|---|---|
| ACS DobfarItalian anti-infectives specialist (1973). Vertically integrated: cephalosporin/carbapenem/penicillin APIs AND finished dosage on a CDMO basis. | Tribiano | Family-owned | Tier 1 | not disclosed | Small-molecule API, Sterile fill-finish, Oral solid dose | high |
| Biofarma GroupItalian/European leader in third-party-exclusive dev, manufacture and packaging of food supplements, probiotic drugs, medical devices. | Mereto di Tomba | Private equityArdian | Tier 1 | €443.3 m | Oral solid dose | high |
| BSP PharmaceuticalsLeading oncology CDMO: ADC conjugation + highly-potent aseptic fill-finish from clinical to commercial. Serves ~80 countries. | Latina | Family-ownedBraca family | Tier 1 | €532.7 m (2024) | Sterile fill-finish, Antibody-drug conjugate (ADC), Monoclonal antibody, Oral solid dose | high |
| F.I.S. Fabbrica Italiana SinteticiOne of the largest small-molecule API CDMOs in the world. Strong GLP-1 growth. Controlled by Bain Capital since 2023. | Montecchio Maggiore | Private equityBain Capital | Tier 1 | €879 m (2025) | Small-molecule API | high |
| OlonOne of Europe's largest API CDMOs; absorbed Euticals. Chemical synthesis + microbial fermentation, HPAPI, ADC bioconjugation. | Rodano | Family-owned | Tier 1 | ~€546 m (2024, group) | Small-molecule API, Microbial and protein, Peptide, Antibody-drug conjugate (ADC), Biologics and biosimilars | high |
| Patheon ItaliaItaly CDMO sites of Thermo Fisher (Patheon). Sterile/lyo + high-potency + mRNA/LNP. | Ferentino | Part of a pharma or industrial groupThermo Fisher Scientific | Tier 1 | not disclosed | Sterile fill-finish, Biologics and biosimilars, mRNA and LNP, Small-molecule API | low |
| Aptuit (Evotec)Integrated CMC CDMO of Evotec (Aptuit acquired 2017). GMP API drug substance + drug-product to commercial scale. | Verona | Part of a pharma or industrial groupEvotec | Tier 2 | not disclosed | Small-molecule API, Oral solid dose | medium |
| Cambrex Profarmaco MilanoItalian operating entity of US-HQ Cambrex; generic APIs + custom/contract manufacturing of APIs and intermediates. | Paullo | Private equityCambrex (Permira) | Tier 2 | not disclosed | Small-molecule API | medium |
| ChemiCustom/contract API manufacturing plus complex generics and proprietary peptides, low-molecular-weight heparins. | Cinisello Balsamo | Part of a pharma or industrial groupItalfarmaco Group | Tier 2 | not disclosed | Small-molecule API, Peptide, Biologics and biosimilars | high |
| Delpharm MilanoItalian operating CDMO plant of French group Delpharm; site acquired from Roche (2017); oral solid dosage + packaging. | Segrate | Part of a pharma or industrial groupDelpharm (France) | Tier 2 | not disclosed | Oral solid dose | medium |
| Dipharma FrancisGlobal CDMO + generic API manufacturer (>40 APIs) plus exclusive/custom synthesis. FDA-inspected. | Baranzate | Family-owned | Tier 2 | not disclosed | Small-molecule API | medium |
| Doppel FarmaceuticiFull-service finished-dose CDMO: solids, semi-solids, liquids, sprays, and aseptic/terminally-sterilized injectable vials. | Cortemaggiore | Private equityTrilantic Europe | Tier 2 | €112.8 m (2024) | Oral solid dose, Sterile fill-finish | high |
| FarmabiosWorld leader in steroid chemistry (>80 APIs) + CDMO for HPAPIs, cytotoxics, hormones. Italian site of Axplora group. | Gropello Cairoli | Private equityAxplora | Tier 2 | not disclosed | Small-molecule API | high |
| Fine Foods & Pharmaceuticals N.T.M.Contract dev & manufacturing of oral solid forms for pharma and nutraceutical clients; serves 60+ pharma companies. Listed. | Zingonia-Verdellino | Listed | Tier 2 | not disclosed | Oral solid dose | high |
| FlammaFamily-owned small-molecule API CDMO since 1950; leader in amino acids and peptide building blocks. FDA-inspected. | Chignolo d'Isola | Family-ownedNegrisoli family | Tier 2 | not disclosed | Small-molecule API, Peptide | high |
| GeneticLeading Italian CDMO in respiratory + ophthalmic. BFS sterile monodose, eye drops, nasal sprays, pMDI/DPI inhalers. | Fisciano | Private equityRenaissance Partners | Tier 2 | not disclosed | Sterile fill-finish, Oral solid dose | high |
| Haupt Pharma LatinaAenova Group's designated central sterile site. Third-party sterile fill-finish plus beta-lactam injectables and oral solids. | Latina | Part of a pharma or industrial groupAenova Group | Tier 2 | not disclosed | Sterile fill-finish, Oral solid dose, Monoclonal antibody, Peptide, Biologics and biosimilars | low |
| ICE (Industria Chimica Emiliana)World-leading integrated producer of bile-acid APIs (UDCA, TUDCA); custom-CDMO role narrower. Founded 1949. | Reggio Emilia | Family-owned | Tier 2 | not disclosed | Small-molecule API | medium |
| LabomarNutraceutical/food-supplement finished-dose CDMO (supplements, medical devices, pharmaceuticals) for third parties. | Istrana | Private equityCharterhouse Capital | Tier 2 | €135 m (2025) | Oral solid dose | low |
| Morpho (Alfasigma CDMO)Alfasigma's dedicated third-party CDMO unit (rebranded 'Morpho' 2024). Sterile injectables, lyophilized products, vaccines, oral solids. | Bologna | Part of a pharma or industrial groupAlfasigma | Tier 2 | not disclosed | Sterile fill-finish, Oral solid dose, Biologics and biosimilars | high |
| PROCOSCustom synthesis (~70% of turnover) + generic APIs; active in HPAPI and ADC drug-linkers. Owned by Japan's CBC. | Cameri | Part of a pharma or industrial groupCBC Group (Japan) | Tier 2 | €233.8 m (2024) | Small-molecule API, Antibody-drug conjugate (ADC) | high |
| Special Product's Line (SPL)Italian CDMO specialized in non-sterile finished dose: oral solids, liquids and semi-solids for 60+ clients. EU-GMP. | Anagni | Family-owned | Tier 2 | not disclosed | Oral solid dose | high |
| Bioindustria L.I.M.Own + third-party manufacturing. Sterile injectable/freeze-dried solutions and non-sterile tablets/capsules; also an API dept. | Novi Ligure | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose, Small-molecule API | high |
| ErregierreFamily company (1974) making small/medium-volume APIs (human + veterinary); contract manufacturing + DMF/CEP support. | San Paolo d'Argon | Family-ownedGargani family | Tier 3 | not disclosed | Small-molecule API | high |
| IBI LorenziniAseptic manufacturing of sterile injectables (specialist in sterile penicillins/cephalosporins) plus oral, topical and biotech. | Aprilia | Family-ownedIbigen Group | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose, Biologics and biosimilars, Monoclonal antibody, Peptide | high |
| Lamp San ProsperoItalian oral-solid-dose CDMO. Non-biologics tier-3 addition for completeness. | San Prospero | Family-owned | Tier 3 | not disclosed | Oral solid dose, Small-molecule API | medium |
| NerPharMaHPAPI/oncology CDMO offering integrated drug substance + drug product: injectables and oral solids. EMA + FDA accredited. | Nerviano | Part of a pharma or industrial groupBenta Group (Lebanon) | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose, Biologics and biosimilars, Small-molecule API | high |
| NewchemItalian API maker (1998) specializing in steroids, hormones, prostaglandins; custom synthesis + contract (~53 APIs). | Milan | Part of a pharma or industrial groupZhejiang Xianju (China) | Tier 3 | not disclosed | Small-molecule API | high |
| PierrelListed Italian company. Contract-manufacturing division does aseptic small-volume parenteral fill for external clients. | Capua | Listed | Tier 3 | €53.7 m (2024) | Sterile fill-finish | high |
| S.A.L.F. Laboratorio FarmacologicoInjectable/infusion sterile solutions (ampoules, bottles, bags) — own portfolio plus explicit contract manufacturing. Since 1921. | Cenate Sotto | Family-ownedAngeletti family | Tier 3 | not disclosed | Sterile fill-finish | high |
| Zach SystemFine-chemical/API arm of Italy's Zambon group; Italian API production divested to FIS, remaining manufacturing in France. | Bresso | Part of a pharma or industrial groupZambon | Tier 3 | not disclosed | Small-molecule API | medium |
Size: Tier 1 (revenue over €1bn) · Tier 2 (€250m–€1bn) · Tier 3 (under €250m or niche).
Revenue, staff and site figures are as reported and mix audited accounts with commercial estimates, which are often wrong for private companies. Each row carries a confidence mark; verify a figure before quoting it.
Browse the census
Other European CDMO lists
By country
- CDMOs in Italy
- CDMOs in Spain (30)
- CDMOs in Germany (28)
- CDMOs in the United Kingdom (25)
- CDMOs in France (15)
- CDMOs in Switzerland (14)
- CDMOs in Poland (11)
- CDMOs in Belgium (9)
- CDMOs in Sweden (9)
- CDMOs in Greece (8)
- CDMOs in Ireland (8)
- CDMOs in the Netherlands (8)
- CDMOs in Portugal (8)
- CDMOs in Denmark (7)
- CDMOs in Austria (5)
- CDMOs in Finland (5)
- CDMOs in Norway (5)
- CDMOs in Czechia (4)
- CDMOs in Lithuania (4)
- CDMOs in Bulgaria (3)
By modality
- Small-molecule API CDMOs in Europe (107)
- Oral solid dose CDMOs in Europe (94)
- Sterile fill-finish CDMOs in Europe (106)
- Biologics and biosimilars CDMOs in Europe (66)
- Monoclonal antibody CDMOs in Europe (36)
- Antibody-drug conjugate (ADC) CDMOs in Europe (15)
- Cell and gene therapy CDMOs in Europe (29)
- mRNA and LNP CDMOs in Europe (22)
- Viral vector and vaccine CDMOs in Europe (32)
- Microbial and protein CDMOs in Europe (34)
- Peptide CDMOs in Europe (24)